SC
REGN icon

Schubert & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Schubert & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23
Closed -$18.9K – 1176
2023
Q1 		$18.9K Buy
23
+1
+5% +$754 0.02% 136
2022
Q4 		$15.9K Buy
22
+4
+22% +$2.95K 0.01% 138
2022
Q3 		$12K Buy
18
+2
+13% +$1.26K 0.01% 169
2022
Q2 		$9K Buy
16
+7
+78% +$4.55K 0.01% 196
2022
Q1 		$6K Hold
9
– – 0.01% 153
2021
Q4 		$6K Buy
+9
New +$5.53K 0.01% 129

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Schubert & Co's REGN Position: Q2 2023 in Review

Schubert & Co sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 23 shares — an estimated $18.9K sold.

Schubert & Co first reported a position in REGN in Q4 2021 and held it in 6 quarters. The position peaked at $18.9K in Q1 2023. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • Schubert & Co reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 23 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $18.9K.
  • Schubert & Co first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Regeneron Pharmaceuticals position peaked at $18.9K in Q1 2023.
  • 1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.